Prävalenz des Hepatitis-C-Virus bei Blutspendern und Vergleich von vier verschiedenen Anti-HCV-Differenzierungstests.

H. Hennig; D. Haase; H. Kirchner

Prävalenz des Hepatitis-C-Virus bei Blutspendern und Vergleich von vier verschiedenen Anti-HCV-Differenzierungstests.

Translated title of the contribution: Prevalence of hepatitis C virus in blood donors and comparison of 4 different anti-HCV differentiation tests

H. Hennig^*, D. Haase, H. Kirchner

^*Corresponding author for this work

2 Citations (Scopus)

Abstract

In 1994 we tested 30,208 blood donations in Lübeck with the Abbott HCV EIA 2.0. 88 specimens of 47 blood donors who were repeatedly reactive were the basis of comparative investigations with the Chiron RIBA HCV 2.0 and 3.0, the Abbott Matrix HCV, the Wellcozyme HCV Western Blot (Murex) and the PCR (Amplicor HCV Test, Roche Diagnostic Systems). Our results suggest that the minimal prevalence of HCV RNA amounts to approximately 0.13%, the incidence per year to 0.013%. The minimal prevalence of anti-HCV amounts to 0.27%. Anti-core antibodies are the most frequent anti-HCV antibodies. They may be the only detectable antibodies during the early phase of the infection. The Chiron RIBA HCV 3.0 with the synthetic peptide c22p is not sufficiently sensitive for anti-core antibodies and may therefore fail to recognize viremic specimens.

Translated title of the contribution	Prevalence of hepatitis C virus in blood donors and comparison of 4 different anti-HCV differentiation tests
Original language	German
Journal	Beiträge zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine
Volume	33
Pages (from-to)	231-234
Number of pages	4
ISSN	1023-2028
Publication status	Published - 1996

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

@article{0fddd0c6e63a41cca38c830273a17d9c,

title = "Pr{\"a}valenz des Hepatitis-C-Virus bei Blutspendern und Vergleich von vier verschiedenen Anti-HCV-Differenzierungstests.",

abstract = "In 1994 we tested 30,208 blood donations in L{\"u}beck with the Abbott HCV EIA 2.0. 88 specimens of 47 blood donors who were repeatedly reactive were the basis of comparative investigations with the Chiron RIBA HCV 2.0 and 3.0, the Abbott Matrix HCV, the Wellcozyme HCV Western Blot (Murex) and the PCR (Amplicor HCV Test, Roche Diagnostic Systems). Our results suggest that the minimal prevalence of HCV RNA amounts to approximately 0.13%, the incidence per year to 0.013%. The minimal prevalence of anti-HCV amounts to 0.27%. Anti-core antibodies are the most frequent anti-HCV antibodies. They may be the only detectable antibodies during the early phase of the infection. The Chiron RIBA HCV 3.0 with the synthetic peptide c22p is not sufficiently sensitive for anti-core antibodies and may therefore fail to recognize viremic specimens.",

author = "H. Hennig and D. Haase and H. Kirchner",

note = "Copyright: This record is sourced from MEDLINE{\textregistered}/PubMed{\textregistered}, a database of the U.S. National Library of Medicine",

year = "1996",

language = "Deutsch",

volume = "33",

pages = "231--234",

journal = "Beitr{\"a}ge zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine",

issn = "1023-2028",

}

Prävalenz des Hepatitis-C-Virus bei Blutspendern und Vergleich von vier verschiedenen Anti-HCV-Differenzierungstests. / Hennig, H.; Haase, D.; Kirchner, H.
In: Beiträge zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine, Vol. 33, 1996, p. 231-234.

Research output: Journal Articles › Journal articles › Research › peer-review

TY - JOUR

T1 - Prävalenz des Hepatitis-C-Virus bei Blutspendern und Vergleich von vier verschiedenen Anti-HCV-Differenzierungstests.

AU - Hennig, H.

AU - Haase, D.

AU - Kirchner, H.

N1 - Copyright: This record is sourced from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

PY - 1996

Y1 - 1996

N2 - In 1994 we tested 30,208 blood donations in Lübeck with the Abbott HCV EIA 2.0. 88 specimens of 47 blood donors who were repeatedly reactive were the basis of comparative investigations with the Chiron RIBA HCV 2.0 and 3.0, the Abbott Matrix HCV, the Wellcozyme HCV Western Blot (Murex) and the PCR (Amplicor HCV Test, Roche Diagnostic Systems). Our results suggest that the minimal prevalence of HCV RNA amounts to approximately 0.13%, the incidence per year to 0.013%. The minimal prevalence of anti-HCV amounts to 0.27%. Anti-core antibodies are the most frequent anti-HCV antibodies. They may be the only detectable antibodies during the early phase of the infection. The Chiron RIBA HCV 3.0 with the synthetic peptide c22p is not sufficiently sensitive for anti-core antibodies and may therefore fail to recognize viremic specimens.

AB - In 1994 we tested 30,208 blood donations in Lübeck with the Abbott HCV EIA 2.0. 88 specimens of 47 blood donors who were repeatedly reactive were the basis of comparative investigations with the Chiron RIBA HCV 2.0 and 3.0, the Abbott Matrix HCV, the Wellcozyme HCV Western Blot (Murex) and the PCR (Amplicor HCV Test, Roche Diagnostic Systems). Our results suggest that the minimal prevalence of HCV RNA amounts to approximately 0.13%, the incidence per year to 0.013%. The minimal prevalence of anti-HCV amounts to 0.27%. Anti-core antibodies are the most frequent anti-HCV antibodies. They may be the only detectable antibodies during the early phase of the infection. The Chiron RIBA HCV 3.0 with the synthetic peptide c22p is not sufficiently sensitive for anti-core antibodies and may therefore fail to recognize viremic specimens.

UR - http://www.scopus.com/inward/record.url?scp=0029680054&partnerID=8YFLogxK

M3 - Zeitschriftenaufsätze

C2 - 8974699

AN - SCOPUS:0029680054

SN - 1023-2028

VL - 33

SP - 231

EP - 234

JO - Beiträge zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine

JF - Beiträge zur Infusionstherapie und Transfusionsmedizin = Contributions to infusion therapy and transfusion medicine

ER -

Prävalenz des Hepatitis-C-Virus bei Blutspendern und Vergleich von vier verschiedenen Anti-HCV-Differenzierungstests.

Abstract

UN SDGs

Other files and links

Fingerprint

Cite this